Medical artificial intelligence solutions company AIDOT (CEO: Jaehoon Jung), OrganoidScience (CEO: Jongman Yoo), an innovative bio company specializing in organoids, and SML Biopharm (CEO: Yongkwan Kim), which possesses next-generation mRNA-based innovative technology, announced on the 20th that they have signed a multilateral Memorandum of Understanding (MOU) for "Evaluation models for anti-cancer immune vaccines and new drug development using AI-powered organoids.” This consortium aims to accelerate the commercialization of immune-oncology vaccines utilizing the new modality—mRNA-LNP Platform vaccine technology. The significance of this MOU lies in bringing together three companies, each highly specialized in different fields: artificial intelligence, organoids, and mRNA drug development. Through this agreement, the companies aim to jointly develop new drugs by evaluating drugs developed using organoid models and validating them through AI solutions. Yongkwan Kim, CEO of SML Biopharm, which is developing a variety of immune-oncology and anti-infective vaccines such as for cervical cancer and head and neck cancer using next-generation innovative mRNA-LNP platforms, stated that he expects this joint research to greatly contribute to life sciences and medicine. By combining the technologies owned by each company, they hope to not only develop mRNA platform-based immune-oncology vaccines but also move toward developing personalized cancer vaccines. Meanwhile, Jongman Yoo, CEO of OrganoidScience, expressed high expectations, saying that by utilizing their tumor organoid platform, Odyssey Onco, they can jointly move beyond efficacy evaluation and mechanism elucidation for anti-cancer drug candidates to actual drug development collaboration. Jaehoon Jung, CEO of AIDOT, also remarked that he is pleased for the opportunity to conduct R&D through exchanges among companies with exceptional technologies and expertise in their respective fields. He expects that providing AI biomarker standards—such as for cervical cancer—through this multi-party agreement will lead to successful new drug development and ultimately drive paradigm shifts in cancer therapy. 

Hankyung TV / 2023.12.21 / Senior Reporter Jaejun Yang